In recent years, the alarming increase of antibiotic resistance, compounded by the simultaneous decrease in development of new antibiotics, has created serious concerns for public health. Moreover, current antibiotics also target the beneficial commensal microbes (microbiota) that inhabit our body, sometimes with significant health consequences. The answer to the antibiotic crisis thus involves broad, creative efforts to develop new treatments for infectious agents. Here I discuss what can be learned from investigating microbial competition in vivo and how this knowledge can be utilized to devise new narrow-spectrum therapeutics that target bacterial pathogens while minimizing deleterious effects to the microbiota.

中文翻译：

---

从宿主中的细菌竞争中学习发展抗菌素。

近年来，令人惊讶的抗生素耐药性增加，同时新抗生素的开发同时减少，已经引起了公众健康的严重关注。此外，当前的抗生素还针对居住在我们体内的有益共生微生物（微生物群），有时会对健康造成重大影响。因此，抗生素危机的解决方案涉及广泛的创造性工作，以开发针对传染性疾病的新疗法。在这里，我讨论了从研究体内微生物竞争中可以学到的知识，以及如何利用这些知识来设计针对细菌病原体的新的窄谱疗法，同时将对微生物群的有害影响降至最低。